The EMBARK trial of enzalutamide for the treatment of prostate cancer with high-risk biochemical recurrence: Improved outcomes versus leuprolide
In this medfyle
The EMBARK trial evaluated the efficacy and safety of enzalutamide plus leuprolide and enzalutamide monotherapy, compared with leuprolide alone, in patients with prostate cancer and high-risk biochemical recurrence. Enzalutamide plus leuprolide and enzalutamide monotherapy both demonstrated significantly longer metastasis-free survival than leuprolide alone.
About this Medfyle
©2024 Medfyle. All rights reserved.
Original article:
Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, Haas GP, Kim CS, Ramirez-Backhaus M, Rannikko A, Tarazi J, Sridharan S, Sugg J, Tang Y, Tutrone RF Jr, Venugopal B, Villers A, Woo HH, Zohren F, Shore ND. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer. N Engl J Med. 2023 Oct 19;389(16):1453-1465. doi: 10.1056/NEJMoa2303974. PMID: 37851874.
The summary content was prepared by Rhian Shurlock for Medfyle, and reviewed by Marianna Aita, MD.
The authors of the original article and the publisher were not involved in the creation of the summary.
